Renal Cell Carcinoma

September 13th 2024

A statistically significant improvement in progression-free survival and objective response rate was seen with belzutifan treatment in patients with previously treated patients with advanced clear cell renal cell carcinoma.

September 6th 2024

There are remaining gaps in papillary renal cell carcinoma that data from 3 pending trials hope to fill.

September 5th 2024

Findings from a subgroup analysis of the phase 3 LITESPARK-005 trial showed that belzutifan demonstrated superior efficacy and safety outcomes vs everolimus across prespecified subgroups.

September 4th 2024

Fianlimab plus cemiplimab was well-tolerated and showed durable responses, in pretreated patients with advanced clear cell renal carcinoma.